NYU Grossman School of Medicine Dermatology

Topics

• Hair Growth and Disorders 432
• Cutaneous Melanoma Detection and Management 396
• Dermatologic Treatments and Research 389
• Psoriasis: Treatment and Pathogenesis 388
• Nonmelanoma Skin Cancer Studies 338
• Autoimmune Bullous Skin Diseases 257
• Systemic Lupus Erythematosus Research 241
• Dermatology and Skin Diseases 230
• Nail Diseases and Treatments 194
• Inflammatory Myopathies and Dermatomyositis 180
• Cutaneous lymphoproliferative disorders research 148
• Acne and Rosacea Treatments and Effects 143

Most cited

1. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.

   Journal for immunotherapy of cancer · 2021 · 762 citations · Mario Lacouture

2. 2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus.

   Arthritis care & research · 2026 · 48 citations · Victoria Werth

3. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.

   Journal of the American Academy of Dermatology · 2023 · 292 citations · Bruce Strober

4. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.

   Journal of the American Academy of Dermatology · 2023 · 241 citations · Bruce Strober

5. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.

   Lancet (London, England) · 2023 · 223 citations · Jerry Shapiro

6. 2021 DORIS definition of remission in SLE: final recommendations from an international task force.